First Eagle Investment Management LLC lessened its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 49.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,580,066 shares of the company's stock after selling 1,545,866 shares during the period. First Eagle Investment Management LLC owned 0.41% of LifeStance Health Group worth $19,008,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of LifeStance Health Group during the 2nd quarter valued at $389,293,000. Dimensional Fund Advisors LP lifted its holdings in LifeStance Health Group by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock valued at $66,038,000 after acquiring an additional 1,461,215 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of LifeStance Health Group during the 2nd quarter valued at about $30,881,000. Bank of America Corp DE acquired a new stake in LifeStance Health Group during the second quarter valued at approximately $14,987,000. Finally, Bank of New York Mellon Corp acquired a new position in LifeStance Health Group in the second quarter worth approximately $11,626,000. Institutional investors and hedge funds own 85.50% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently weighed in on LFST. Wall Street Zen raised LifeStance Health Group from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 14th. KeyCorp raised their price objective on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an "overweight" rating in a research note on Friday, November 6th. JPMorgan Chase & Co. lifted their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Thursday, November 12th. Barclays upped their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an "overweight" rating in a research report on Thursday, September 10th. Finally, Canaccord Genuity Group upped their target price on LifeStance Health Group from $15.00 to $16.00 and gave the company a "buy" rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.86.
Get Our Latest Report on LifeStance Health Group
LifeStance Health Group Stock Down 2.8%
LifeStance Health Group stock opened at $13.77 on Thursday. LifeStance Health Group, Inc. has a fifty-two week low of $6.05 and a fifty-two week high of $15.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of 72.48 and a beta of 1.35. The firm has a fifty day moving average price of $12.88 and a two-hundred day moving average price of $9.78.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The company had revenue of $455.86 million during the quarter, compared to analysts' expectations of $431.59 million. LifeStance Health Group's quarterly revenue was up 25.3% compared to the same quarter last year. As a group, analysts forecast that LifeStance Health Group, Inc. will post 0.18 earnings per share for the current year.
Insider Buying and Selling
In other LifeStance Health Group news, insider Ryan Pardo sold 2,216,585 shares of the business's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $14.58, for a total value of $32,317,809.30. Following the sale, the insider owned 334,935 shares of the company's stock, valued at $4,883,352.30. The trade was a 86.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Lisa Miller sold 14,663 shares of LifeStance Health Group stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $14.68, for a total transaction of $215,252.84. Following the sale, the chief operating officer owned 251,904 shares in the company, valued at approximately $3,697,950.72. This trade represents a 5.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 2,861,235 shares of company stock valued at $41,646,338 over the last ninety days. 3.50% of the stock is owned by company insiders.
LifeStance Health Group Company Profile
(
Free Report)
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance's clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Read More
Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.